Todd C. Davis - 14 Feb 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Issuer symbol
LGND
Transactions as of
14 Feb 2026
Net transactions value
-$6,043,779
Form type
4
Filing time
18 Feb 2026, 16:21:54 UTC
Previous filing
08 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis Todd C Chief Executive Officer, Director 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis 18 Feb 2026 0001392029

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +20,782 +13% $0.000000 182,119 14 Feb 2026 Direct F1
transaction LGND Common Stock Tax liability $1,503,362 -8,178 -4.5% $183.83 173,941 14 Feb 2026 Direct F2
transaction LGND Common Stock Award $0 +39,644 +23% $0.000000 213,585 14 Feb 2026 Direct F1
transaction LGND Common Stock Tax liability $2,867,748 -15,600 -7.3% $183.83 197,985 14 Feb 2026 Direct F2
transaction LGND Common Stock Tax liability $374,829 -2,039 -1% $183.83 195,946 15 Feb 2026 Direct F3
transaction LGND Common Stock Tax liability $782,197 -4,255 -2.2% $183.83 191,691 15 Feb 2026 Direct F3
transaction LGND Common Stock Tax liability $515,643 -2,805 -1.5% $183.83 188,886 15 Feb 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs").
F2 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs.
F3 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.